Introduction

• 1  Rowell NR. Some historical aspects of skin disease in lupus erythematosus. Lupus 1997;6:76–83. Cross Ref link Pubmed link
• 2  Rowell NR. The natural history of lupus erythematosus. Clin Exp Dermatol 1984;9:217–31. Cross Ref link Pubmed link
• 3  Provost T. The relationship between discoid and systemic lupus erythematosus. Arch Dermatol 1994;130:1308–9. Cross Ref link Pubmed link
• 4  Halmi BH, Dileomondo M, Jacoby RA. Classification of lupus erythematosus. Int J Dermatol 1993;32:643–4. Cross Ref link Pubmed link
• 5  Dubois EL, ed. Lupus Erythematosus, 2nd edn. Berkeley, CA: University of Southern California Press, 1976:446.
• 6  Kierland RR. Classification of cutaneous manifestations of lupus erythematosus. Proc Staff Meet Mayo Clin 1940;15:674.
• 7  Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus. Arch Dermatol 1979;115:1409–15. Cross Ref link Pubmed link
• 8  Ganor S, Sagher F. Systemic lupus erythematosus changing to the chronic discoid type. Dermatologica 1962;125:81–92. Cross Ref link Pubmed link
• 9  Cannon EF, Curtis AC. A survey of lupus erythematosus in the University of Michigan Hospital since 1948. Arch Dermatol 1958;78:196–9. Cross Ref link
• 10  Millard LG, Rowell NR. Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. Arch Dermatol 1979;115:1055–8. Cross Ref link Pubmed link
• 11  Shrank AB, Doniach D. Discoid lupus erythematosus. Arch Dermatol 1963;87:677–85. Cross Ref link Pubmed link
• 12  Rothfield N, March CH, Miescher P, et al. Chronic discoid lupus erythematosus: study of 65 patients and 65 controls. N Engl J Med 1963;269:1155–61. Cross Ref link Pubmed link
• 13  Rowell NR. Laboratory abnormalities in the diagnosis and management of lupus erythematosus. Br J Dermatol 1971;84:210–16. Cross Ref link Pubmed link
• 14  Healy E, Kieran E, Rogers S. Cutaneous lupus erythematosus – a study of clinical and laboratory prognostic factors in 65 patients. Ir J Med Sci 1995;164:113–15. Cross Ref link Pubmed link
• 15  Tuffanelli DL. Cutaneous immunopathology: recent observations. J Invest Dermatol 1975;65:143–53. Cross Ref link Pubmed link
• 16  Burch PRJ, Rowell NR. Systemic lupus erythematosus. Am J Med 1965;38:793–801. Cross Ref link Pubmed link
• 17  Burch PRJ, Rowell NR. Autoimmunity: aetiological aspects of chronic discoid and systemic lupus erythematosus, systemic sclerosis and Hashimoto's thyroiditis. Lancet 1963;ii:507–13. Cross Ref link
• 18  Burch PRJ, Rowell NR. The sex and age‐distribution of chronic discoid lupus erythematosus in four countries. Acta Derm Venereol (Stockh) 1968;48:33–46.
• 19  Burch PRJ, Rowell NR. Lupus erythematosus. Analysis of the sex‐ and age‐distributions of the discoid and systemic forms of the disease in different countries. Acta Derm Venereol (Stockh) 1970;50:293–301.
• 20  Burnet FM. The Clonal Selection Theory of Acquired Immunity. Nashville, TN: Vanderbilt University Press, 1959. Cross Ref link
• 21  Tsuchiya N, Ohashi J, Tokunaga K. Variations in immune response genes and their associations with multifactorial immune disorders. Immunol Rev 2002;190:169–81. Cross Ref link Pubmed link
• 22  Millard LG, Rowell NR, Rajah SM. Histocompatibility antigens in discoid and systemic lupus erythematosus. Br J Dermatol 1977;96:139–44. Cross Ref link Pubmed link
• 23  Van der Linden MW, van der Slik AR, Zanelli E, et al. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA‐DR3 and TNF‐308A in systemic lupus erythematosus. Genes Immun 2001;2:373–80. Cross Ref link Pubmed link
• 24  Beck JS, Oakley CL, Rowell NR. Transplacental passage of anti‐nuclear antibody. Arch Dermatol 1966;93:656–63. Cross Ref link Pubmed link

Discoid lupus erythematosus

• 25  Lipsker D. The need to revisit the nosology of cutaneous lupus erythematosus: the current terminology and morphologic classification of cutaneous LE: difficult, incomplete and not always applicable. Lupus 2010;19:1047–9. Cross Ref link Pubmed link
• 26  Cozzani E, Christana K, Rongioletti F, Rebora A, Parodi A. Lupus erythematosus tumidus: clinical, histopathological and serological aspects and therapy response of 21 patients. Eur J Dermatol 2010;20:797–801. Pubmed link
• 27  Lipsker D, Mitschler A, Grosshans E, Cribier B. Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology 2006;213:15–22. Cross Ref link Pubmed link
• 28  Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population‐based cohort of 1088 patients in Sweden. Br J Dermatol 2011;164:1335–41. Cross Ref link Pubmed link
• 29  Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population‐based study. Arch Dermatol 2009;145:249–53. Cross Ref link Pubmed link
• 30  Burch PRJ, Rowell NR. The sex‐ and age‐distributions of chronic discoid lupus erythematosus in four countries. Acta Derm Venereol (Stockh) 1968;48:33–46.
• 31  Burch PRJ, Rowell NR. Lupus erythematosus: analysis of the sex‐ and age‐distributions of the discoid and systemic forms of the disease in different countries. Acta Derm Venereol (Stockh) 1970;50:293–301.
• 32  O'Reilly FM, O'Loughlin S, Murphy GM. Discoid lupus erythematosus and porphyria cutanea tarda. J R Soc Med 1996;89:523–4. Pubmed link
• 33  Cram DL, Epstein JH, Tuffanelli DL. Lupus erythematosus and porphyria. Arch Dermatol 1973;108:779–84. Cross Ref link Pubmed link
• 34  Mutasim DF, Pelc NJ. Erythropoietic protoporphyria and lupus erythematosus: case report and review of the literature. Arch Dermatol 1994;130:1330–2. Cross Ref link Pubmed link
• 35  Cruz PD, Jr, Coldiron BM, Sontheimer RD. Concurrent features of cutaneous lupus erythematosus and pemphigus erythematosus following myasthenia gravis and thymoma. J Am Acad Dermatol 1987;16: 472–80. Cross Ref link Pubmed link
• 36  Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 2007;33(1–2):85–106. Cross Ref link Pubmed link
• 37  Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol 2014;47:148–62. Cross Ref link Pubmed link
• 38  Al‐Refu K, Goodfield M. Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus. Autoimmun Rev 2009;8:474–7. Cross Ref link Pubmed link
• 39  Wenzel J,Uerlich E, Worrenkamper S, et al. Scarring skin lesions of discoid lupus erythematosus are characterised by high numbers of skin‐homing cytotoxic lymphocytes associated with strong expression of the type 1 interferon‐induced protein MxA. Br J Dermatol 2005;153:1011–17. Cross Ref link Pubmed link
• 40  Wenzel J, Wörenkämper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1‐biased inflammation in cutaneous lupus erythematosus. J Pathol 2005;205:435–42. Cross Ref link Pubmed link
• 41  Zahn S, Rehkämper C, Kümmerer BM, et al. Evidence for a pathophysiological role of keratinocyte‐derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol 2011;131:133–40. Cross Ref link Pubmed link
• 42  Zahn S, Rehkämper C, Ferring‐Schmitt S, Bieber T, Tüting T, Wenzel J. Interferon‐α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol 2011;165:1118–23. Cross Ref link Pubmed link
• 43  Franz B, Fritzsching B, Riehl A, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007;56:1910–20. Cross Ref link Pubmed link
• 44  Chong BF, Tseng LC, Kim A, et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci 2014;73:216–24. Cross Ref link Pubmed link
• 45  Elkon KB, Sontheimer C. Editorial: Toll‐like receptor 7: more than skin deep? Arthritis Rheumatol 2014;66:481–4. Cross Ref link Pubmed link
• 46  Lodin A. Discoid lupus erythematosus and trauma. Acta Derm Venereol (Stockh) 1963;43:142.
• 47  Eedy DJ, Corbett JR. Discoid lupus erythematosus exacerbated by X‐ray irradiation. Clin Exp Dermatol 1988;13:202–3. Cross Ref link Pubmed link
• 48  Schmitt CL, Silverman A. Discoid lupus erythematosus in an arc welder. Cutis 1971;8:476–7.
• 49  Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus 2006;15:724–7. Cross Ref link Pubmed link
• 50  Domke HF, Ludwigsen E, Thormann J. Discoid lupus erythematosus possibly due to photochemotherapy. Arch Dermatol 1979;115:642. Cross Ref link Pubmed link
• 51  Wolfe JT, Weinberg JM, Elenitses R, et al. Cutaneous lupus erythematosus following laser‐induced thermal injury. Arch Dermatol 1997;133:392–3. Cross Ref link Pubmed link
• 52  Lupton GP. Discoid lupus erythematosus occurring in a smallpox vaccination scar. J Am Acad Dermatol 1987;89:688–90. Cross Ref link
• 53  Grundwald M, David M, Feuerman EJ. Appearance of lupus erythematosus in a patient with lichen planus treated by isoniazid. Dermatologica 1982;162:172–7. Cross Ref link
• 54  Burns DA, Sarkany I. Penicillamine‐induced discoid lupus erythematosus. Clin Exp Dermatol 1979;4:389–92. Cross Ref link Pubmed link
• 55  Alexander S. Lupus erythematosus in two patients after griseofulvin treatment of Trichophyton rubrum infection. Br J Dermatol 1962;74:72–4. Cross Ref link Pubmed link
• 56  Helm TN, Jones CM Chilblain lupus erythematosus lesions precipitated by the cold. Cutis 2002;69:183–4. Pubmed link
• 57  Jerdan MS, Hood AF, Moore GW, Callen JP. Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 1990;126:52–5. Cross Ref link Pubmed link
• 58  Obermoser G, Sontheimer RD, Zelger B.Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010;19:1050–70. Cross Ref link Pubmed link
• 59  Weigand DA, Bungdorf HC, Gregg LJ. Dermal mucinosis in discoid lupus erythematosus. Arch Dermatol 1981;117:735–8. Cross Ref link Pubmed link
• 60  Kano Y, Sagawa Y, Yagita A, Nagashima M. Nodular cutaneous lupus mucinosis: report of a case and review of previously reported cases. Cutis 1996;57:441–4. Pubmed link
• 61  Doria A, Canova M, Tonon M, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008;8:24–8. Cross Ref link Pubmed link
• 62  Steagall RW, Ash HT, Fentanco LB. Familial lupus erythematosus. Arch Dermatol 1962;85:394–6. Cross Ref link Pubmed link
• 63  Wojnarowska F. Simultaneous occurrence in identical twins of discoid lupus erythematosus and polymorphic light eruption. J R Soc Med 1983;76:791–2. Pubmed link
• 64  Millard TP, Lewis CM, Khamashta MA, et al. Familial clustering of polymorphic light eruption in relatives of patients with lupus erythematosus: evidence of a shared pathogenesis. Br J Dermatol 2001;144:334–8. Cross Ref link Pubmed link
• 65  Millard LG, Rowell NR, Rajah SM. Histocompatibility antigens in discoid and systemic lupus erythematosus. Br J Dermatol 1977;96:139. Cross Ref link Pubmed link
• 66  Tongio MM, Fersing J, Hauptmann G, et al. HLA antigens in discoid lupus erythematosus. Acta Derm Venereol (Stockh) 1982;62:155–7.
• 67  Millard TP, Kondeatis E, Vaughan RW, et al. Polymorphic light eruption and the HLA DRB1*0301 extended haplotype are independent risk factors for cutaneous lupus erythematosus. Lupus 2001;10:473–9. Cross Ref link Pubmed link
• 68  Bajaj DR, Devrajani BR, Matlani BL. Discoid lupus erythematosus: a profile. J Coll Phys Surg Pak 2010;20:361–4.
• 69  Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005;4:296–302. Cross Ref link Pubmed link
• 70  Wilson CL, Burge SM, Dean D, et al. Scarring alopecia in discoid lupus erythematosus. Br J Dermatol 1992;126:307–14. Cross Ref link Pubmed link
• 71  Paramsothy Y, Lawrence CM. ‘Tin‐tack’ sign in localized pemphigus foliaceus. Br J Dermatol 1987;116:127–9. Cross Ref link Pubmed link
• 72  Parish LC, Kennedy RJ, Hurley HJ. Palmar lesions in lupus erythematosus. Arch Dermatol 1967;96:273–6. Cross Ref link Pubmed link
• 73  Uitto J, Santa‐Cruz DJ, Eisen AZ, et al. Verrucous lesions in patients with discoid lupus erythematosus. Br J Dermatol 1978;98:507–20. Cross Ref link Pubmed link
• 74  Shuster S. A simple sign of discoid lupus erythematosus. Br J Dermatol 1981;104:350–1. Cross Ref link Pubmed link
• 75  Black AA, McCauliffe DP, Sontheimer RD. Prevalence of acne rosacea in a rheumatic skin disease subspeciality unit. Lupus 1992;1:222–37. Cross Ref link
• 76  Chorzelski TP, Jablonska S, Blaszczyk M, et al. Annular atrophic plaques of the face. Arch Dermatol 1976;112:1143–5. Cross Ref link Pubmed link
• 77  Al‐Refu K, Goodfield M. Scar classification in cutaneous lupus erythematosus: morphological description. Br J Dermatol 2009;161:1052–8. Cross Ref link Pubmed link
• 78  Kabin DI, Malkinson FD. Lupus erythematosus and calcinosis cutis. Arch Dermatol 1969;100:17–22. Cross Ref link Pubmed link
• 79  Pramatarov K. Discoid lupus erythematosus of the soles. J Dermatol 1989;16:511. Cross Ref link Pubmed link
• 80  Rowell NR. The natural history of lupus erythematosus. Clin Exp Dermatol 1984;9:217–31. Cross Ref link Pubmed link
• 81  Crocker HR. Diseases of the Skin: their description, pathology, diagnosis and treatment. Philadelphia: Blakiston, 1888.
• 82  Blanc D, Kienzler JL. Lupus erythematosus gyratus repens: report of a case associated with a lung carcinoma. Clin Exp Dermatol 1982;7:129. Cross Ref link Pubmed link
• 83  Nagy E, Balogh E. Bullous form of chronic discoid erythematoides accompanied by LE‐cell symptoms. Dermatologica 1961;122:6–10. Cross Ref link Pubmed link
• 84  Green JJ, Baker DJ. Linear childhood discoid lupus erythematosus following the lines of Blaschko: a case report with review of the linear manifestations of lupus erythematosus. Pediatr Dermatol 1999;16:128–33. Cross Ref link Pubmed link
• 85  Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus‐a review of literature.Clin Rheumatol 2008;27:1341. Cross Ref link Pubmed link
• 86  Stainforth J, Goodfield MJD, Taylor PV. Pregnancy‐induced chilblain lupus erythematosus. Clin Exp Dermatol 1992;18:449–51. Cross Ref link
• 87  Fraga J, García‐Díez A. Lupus erythematosus panniculitis. Dermatol Clin 2008;26:453–63. Cross Ref link Pubmed link
• 88  Tuffanelli DL. Lupus erythematosus panniculitis (profundus). Arch Dermatol 1971;103:231–42. Cross Ref link Pubmed link
• 89  De Berker D, Dissaneyeka M, Burge S. The sequelae of chronic cutaneous lupus erythematosus. Lupus 1992;1:181–6. Cross Ref link Pubmed link
• 90  Kaposi M. Pathologie und Therapie der Hautkrankheiten, 2nd edn. Vienna: Urban and Schwarzenberg, 1883: 642.
• 91  Irgang S. Lupus erythematosus profundus. Arch Dermatol Syphilol 1940;42:97–102. Cross Ref link
• 92  Pautrier LM. Apropos du pseudo‐lupus erythemateux profond (Kaposi–Irgang). Ann Dermatol Syphilol 1953;80:233–53.
• 93  Pascher F, Sims CF, Pensky N. Lupus erythematosus (Kaposi–Irgang). Reprint of case including comparative study of histopathology with that of chronic discoid lupus erythematosus. J Invest Dermatol 1955;25:347–62. Cross Ref link Pubmed link
• 94  Watanabe T, Tsuchida T. Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 1996;134:123–5. Cross Ref link Pubmed link
• 95  Lipsker D, Mitschler A, Grosshans E, Cribier B. Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology 2006;213:15–22. Cross Ref link Pubmed link
• 96  Fisher DA, Epstein JH, Kay DN, et al. Polymorphous light eruption and lupus erythematosus. Arch Dermatol 1970;101:458–61. Cross Ref link Pubmed link
• 97  Kreuter A, Scola N, Tigges C, Altmeyer P, Gambichler T. Clinical features and efficacy of antimalarial treatment for reticular erythematous mucinosis: a case series of 11 patients. Arch Dermatol 2011;147:710–15. Cross Ref link Pubmed link
• 98  Braun‐Falco O, Bergner T, Heilgemier GP. Pseudopelade alopecia. Hautarzt 1989;40:77–83. Pubmed link
• 99  Van der Horst JC, Cirkel PKS, Nieboer C. Mixed lichen planus/lupus erythematosus disease: a distinct entity? Clinical, histopathological and immunopathological studies in six patients. Clin Exp Dermatol 1983;8:631–40. Cross Ref link Pubmed link
• 100  Potts EDA, Rowell NR. Lichen planus: a distinct entity from lupus erythematosus. Arch Dermatol 1981;61:413–16.
• 101  Santa Cruz DJ, Uitto J, Eisen AZ, et al. Verrucous lupus erythematosus: ultrastructural studies on a distinct variant of chronic discoid lupus erythematosus. J Am Acad Dermatol 1983;9:82–90. Cross Ref link Pubmed link
• 102  Singh R, Bharu K, Ghazali W, Bharu K, Nor M, Kerian K. Tinea faciei mimicking lupus erythematosus. Cutis 1994;53:297–8. Pubmed link
• 103  Das A, Ghosh A, Shome K. Plaque‐type polymorphous light eruption. Indian Pediatr 2014;51:84. Cross Ref link Pubmed link
• 104  Lee LA. Cutaneous lupus in infancy and childhood. Lupus 2010;19:1112–17. Cross Ref link Pubmed link
• 105  McGowan J, Maize J, Cook J. Lupus‐like histopathology in bloom syndrome: reexamining the clinical and histologic implications of photosensitivity. Am J Dermatopathol 2009;31:786–91. Cross Ref link Pubmed link
• 106  Klein R, Moghadam‐Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203–8. Cross Ref link Pubmed link
• 107  Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010;19:1036–46. Cross Ref link Pubmed link
• 108  Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus – a review of literature. Clin Rheumatol 2008;27:949–54 Cross Ref link Pubmed link
• 109  Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011;65:e179–93. Cross Ref link Pubmed link
• 110  Doeglas HMG. Follow‐up of patients with chronic discoid lupus erythematosus. Dermatologica 1963;127:211–15. Cross Ref link Pubmed link
• 111  Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence‐based evaluation. Eur J Clin Pharmacol 2008;64:337–41. Cross Ref link Pubmed link
• 112  Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009;Issue 4:CD002954. Pubmed link
• 113  Fielder A, Graham E, Jones SK, Silman A, Tullo A. Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye 1998;12:907–9. Cross Ref link Pubmed link
• 114  Olansky AJ. Antimalarials and ophthalmologic safety. J Am Acad Dermatol 1982;6:19–23. Cross Ref link Pubmed link
• 115  Feldmann R, Saloan D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment resistant chronic and sub‐acute cutaneous lupus erythematosus. Dermatology 1994;189:425–7. Cross Ref link Pubmed link
• 116  Callen JP. Management of “refractory” skin disease in patients with lupus erythematosus. Best Pract Res Rheumatol 2005;19:767–84. Cross Ref link
• 117  Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: experience in 16 consecutive patients. Br J Rheumatol 1997;36:353–9. Cross Ref link Pubmed link
• 118  Housman TS, Jorizzo JL, McCarty MA, et al. Low‐dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003;139:50–4. Cross Ref link Pubmed link
• 119  Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004;15:46–50. Cross Ref link Pubmed link
• 120  Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Lupus 2010;19:744–7. Cross Ref link Pubmed link
• 121  Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007;143:873–7. Cross Ref link Pubmed link
• 122  Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab‐based B‐cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature. Lupus 2013;22:932–9. Cross Ref link Pubmed link
• 123  Manzi S, Sánchez‐Guerrero J, Merrill JT, et al. BLISS‐52 and BLISS‐76 study groups. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833–8. Cross Ref link Pubmed link
• 124  Momose Y, Arai S, Eto H, Kishimoto M, Okapi M. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus. J Dermatol 2013;40:94–7. Cross Ref link Pubmed link
• 125  Lesiak A, Narbutt J, Kobos J, et al. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin Exp Dermatol 2009;34:570–5. Cross Ref link Pubmed link
• 126  Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992;127:513–18. Cross Ref link Pubmed link
• 127  Dalziel K, Going S, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986;115:211–16. Cross Ref link Pubmed link
• 128  Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982;106:105–6. Cross Ref link Pubmed link
• 129  Bottomley WW, Goodfield MJD. Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 1995;133:655–6. Cross Ref link Pubmed link
• 130  Yell JA, Burge SM. Cyclosporin and discoid lupus erythematosus. Br J Dermatol 1994;131:132–3. Cross Ref link Pubmed link
• 131  Delaporte E, Catteau B, Sabbagh N, et al. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases.] Ann Dermatol Venereol 1997;124:151–6. Pubmed link
• 132  Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991;24:49–52. Cross Ref link Pubmed link
• 133  Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 1974;91:93–6. Cross Ref link Pubmed link
• 134  Rodriguez‐Castellanos MA, Rubio JB, Gomez JFB, Mendoza AG. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 1995;131:620–1. Cross Ref link
• 135  Callen JP, Spencer LV, Burrows JB, Holtman J. Azathioprine: an effective corticosteroid‐sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127:515–22. Cross Ref link Pubmed link
• 136  Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial‐resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011;65:717–21. Cross Ref link Pubmed link
• 137  Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981;20:57–61. Cross Ref link Pubmed link

Subacute cutaneous lupus erythematosus

• 138  Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979;115:1409–15. Cross Ref link Pubmed link
• 139  Callen JP, Klein J. Subacute cutaneous lupus erythematosus: clinical, serologic, immunogenetic, and therapeutic considerations in 72 patients. Arthritis Rheum 1988;31:1007–13. Cross Ref link Pubmed link
• 140  Black DR, Hornung CA, Schneider PD, et al. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol 2002;138:1175–8. Cross Ref link Pubmed link
• 141  Popovic K, Nyberg F, Wahren‐Herlenius M, Nyberg F. A serology‐based approach combined with clinical examination of 125 Ro/SSA‐positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus. Arthritis Rheum 2007;56:255–64. Cross Ref link Pubmed link
• 142  Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013;12:444–54. Cross Ref link Pubmed link
• 143  Amato L, Coronella G, Berti S, et al. Subacute cutaneous lupus erythematosus in childhood. Paediatr Dermatol 2003;20:31–4. Cross Ref link
• 144  Provost TT, Talal N, Harley JB, Reichlin M, Alexander E. The relationship between anti‐Ro (SS‐A) antibody‐positive Sjögren's syndrome and anti‐Ro (SS‐A) antibody‐positive lupus erythematosus. Arch Dermatol 1988;124:63–71. Cross Ref link Pubmed link
• 145  Goette DK. Sweet's syndrome in subacute cutaneous lupus erythematosus. Arch Dermatol 1985;121:789–91. Cross Ref link Pubmed link
• 146  Ashworth J. Subacute cutaneous lupus erythematosus in a patient with Crohn's disease. Clin Exp Dermatol 1992;17:135–6. Cross Ref link Pubmed link
• 147  Grabbe S, Kolde G. Coexisting lichen planus and subacute lupus erythematosus. Clin Exp Dermatol 1995;20:249–56. Cross Ref link Pubmed link
• 148  Ferahbas A, Utas S, Canoz O, et al. The co‐existence of subacute cutaneous lupus erythematosus and psoriasis. J Eur Acad Dermatol Venereol 2004;18:390–1. Cross Ref link Pubmed link
• 149  Gudat W, Bork K. Hereditary angioedema associated with subacute cutaneous lupus erythematosus. Dermatologica 1989;179 211–13. Cross Ref link Pubmed link
• 150  Camp PB, Davis LS. Coexistence of subacute cutaneous lupus erythematosus and porphyria cutanea tarda: a case report. Cutis 1997;59:216E. Pubmed link
• 151  Roberts DL. Subacute cutaneous lupus erythematosus and gluten sensitive enteropathy. Br J Dermatol 1988;118:731–2. Cross Ref link Pubmed link
• 152  Bielsa I, Herrero C, Font J, et al. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987;16:1265–7. Cross Ref link Pubmed link
• 153  Wenzel J, Uerlich M, Gerdsen R, Bieber T, Boehm I. Association of inclusion body myositis with subacute cutaneous lupus erythematosus. Rheumatol Int 2001;21:75–7. Cross Ref link Pubmed link
• 154  Morgan KW, Callen JP. Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 2001;28:2129–32. Pubmed link
• 155  Toll A, Gilaberte M, Matias‐Guiu X, et al. Kikuchi's disease (necrotizing lymphadenitis) with cutaneous involvement associated with subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2004;29:240–3. Cross Ref link Pubmed link
• 156  Rao BK, Coldiron BM, Freeman RF, et al. Subacute lupus erythematosus lesions progressing to morphoea. J Am Acad Dermatol 1990;23:1019–22. Cross Ref link Pubmed link
• 157  Marzano AV, Kolesnikova LV, Gasparini G, et al. Dystrophic calcinosis cutis in subacute lupus. Dermatology 1999;198:90–2. Cross Ref link Pubmed link
• 158  Sonntag M, Lehmann P, Megahed M, et al. Papulonodular mucinosis associated with subacute cutaneous lupus erythematosus. Dermatology 2003;206:326–9. Cross Ref link Pubmed link
• 159  LeFeber WP, Norris DA, Ryan SR, et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 1984;74:1545–51. Cross Ref link Pubmed link
• 160  Jones SK, Coulter S, Harmon C, et al. Ro/SSA antigen in human epidermis. Br J Dermatol 1988;118;363–7. Cross Ref link Pubmed link
• 161  Jones SK. Ultraviolet radiation (UVR) induces cell‐surface Ro/SSA antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR induction of cutaneous lupus lesions. Br J Dermatol 1992;126:546–53. Cross Ref link Pubmed link
• 162  Wang D, Chan EKL. 17b‐Estradiol increases expression of 52‐kDa and 60‐kDa SS‐A/Ro autoantigens in human keratinocytes and breast cancer cell line MCF‐7. J Invest Dermatol 1996;107:610–14. Cross Ref link Pubmed link
• 163  Mellers S, Winterberg F, Gilliet M, et al. Ultraviolet radiation‐induced injury, chemokines and leukocyte recruitment. Arthritis Rheum 2005;52:1504–16. Cross Ref link Pubmed link
• 164  Ioannides D, Golden BD, Buyon JP, et al. Expression of SS‐A/Ro and SS‐B/La antigens in skin biopsy specimens of patients with photosensitive forms of lupus erythematosus. Arch Dermatol 2000;136:340–6. Pubmed link
• 165  Purcell SM, Lieu TS, Davis BM, et al Relationship between circulating anti‐Ro/SS‐A antibody levels and skin disease activity in subacute cutaneous lupus erythematosus. Br J Dermatol 1987;117:277–87. Cross Ref link Pubmed link
• 166  Popovic K, Brauner S, Ek M, et al. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self‐reported cutaneous symptoms induced by sun. Lupus 2007;16:10–17. Cross Ref link Pubmed link
• 167  Dalle Vedove C, Simon JC, Girolomoni G. Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents. J Dtsch Dermatol Ges 2012;10:889–7. Pubmed link
• 168  Sontheimer RD, Henderson CL, Grau RH. Drug‐induced subacute cutaneous lupus erythematosus: a paradigm for bedside‐to‐bench patient‐oriented translational clinical investigation. Arch Dermatol Res 2009;301:65–70. Cross Ref link Pubmed link
• 169  Provost TT, Watson RM. Anti‐Ro (SSA), HLA DR3‐positive females: the inter‐relationship between some ANA negative, SS, SCLE, and NLE mothers and SS/LE overlap female patients. J Invest Dermatol 1993;100:S14–20. Cross Ref link
• 170  Fonseca E, Alvarez R, Gonzalez MR, et al. Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. Lupus 1992;1:265–8. Cross Ref link Pubmed link
• 171  Brown C, Deng J. Thiazide diuretic induces cutaneous lupus‐like cutaneous reaction. J Toxicol Clin Toxicol 1995;33:729–33. Cross Ref link Pubmed link
• 172  Miyagawa S, Okuchi T, Shiomi Y, et al. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol 1989;21:343–6. Cross Ref link Pubmed link
• 173  Farhi D, Viguier M, Cosnes A, et al. Terbinafine‐induced subacute cutaneous lupus erythematosus. Dermatol 2006;212:59–65. Cross Ref link
• 174  Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997;28:67–73. Cross Ref link Pubmed link
• 175  Kurtis B, Larson MJ, Hoang MP, et al. Verapamil‐induced subacute cutaneous lupus erythematosus. J Drug Dermatol 2005;4;506–8.
• 176  Fumal I, Danchin A, Cosserat F, et al. Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: two cases. Dermatol 2005;210:251–2. Cross Ref link
• 177  Fenniche S, Dhaoui A, Amma FB, et al. Acebutalol‐induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol 2005;18:230–3. Cross Ref link Pubmed link
• 178  Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole‐induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol 2005;85:353–4. Pubmed link
• 179  Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007;21:17–24. Cross Ref link Pubmed link
• 180  Srivastava M, Rencic A, Diglio G, et al. Drug induced Ro/SSA positive cutaneous lupus erythematosus. Arch Dermatol 2003;139:45–9. Pubmed link
• 181  Bleumink GS, Ter‐Borg EJ, Ramselaar CG, et al. Etanercept‐induced subacute cutaneous lupus. Rheumatology 2001;40:1317–19. Cross Ref link Pubmed link
• 182  Bentley DD, Graves JE, Smith DI, et al. Efalizumab‐induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006;54:S242–3. Cross Ref link Pubmed link
• 183  High WA, Muldrow ME, Fitzpatrick JE, et al. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol 2005;52;e7–8. Cross Ref link Pubmed link
• 184  Chan SK, Hazleman BL, Burrows NP. Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 2005;30:724–5. Cross Ref link Pubmed link
• 185  Ameio P, Innocente C, Feliciani C, et al. Drug–induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine. Eur J Dermatol 2006;16:281–3. Pubmed link
• 186  Toll A, Campo‐Pisa P, Gonzalez‐Castro J, et al. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus 1998;7:364–6. Cross Ref link Pubmed link
• 187  Pham HC, Saurat JH. Inhalation route inducing subacute cutaneous lupus erythematosus with tiotropium. Arch Dermatol 2005;141:911–12. Cross Ref link Pubmed link
• 188  Cassis TB, Callen JP. Bupropion induced subacute cutaneous lupus erythematosus. Austral J Dermatol 2005;46:266–9. Cross Ref link
• 189  Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004;31:818–20. Pubmed link
• 190  Reich A, Bialynick‐Birula R, Szepietowski JC. Drug‐induced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol 2006;45:1112–14. Cross Ref link Pubmed link
• 191  Balsa A, Bernad M, de Miguel E, et al. Lupus eritematoso cutanoe subagudo por la crisoterapia en una arthritis reumatoide. Rev Clin Esp 1988;182:505–6. Pubmed link
• 192  Parodi A, Rivara G, Guarrera M. Possible naproxen induced relapse of subacute cutaneous lupus erythematosus. JAMA 1992;268:51–2. Cross Ref link Pubmed link
• 193  Leroy D, Dompmartin A, Le Jean S, et al. Dermatitis caused by aldactone of a lupic annular erythema type. Ann Dermatol Venereol 1987;114:1237–40. Pubmed link
• 194  Shapiro M, Sosis AC, Junkins‐Hopkins JM, et al. Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. Int J Dermatol 2004;43:87–94. Cross Ref link Pubmed link
• 195  Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug‐induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011;164:465–72. Pubmed link
• 196  Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population‐based cohort of 1088 patients in Sweden. Br J Dermatol 2011;164:1335–41. Cross Ref link Pubmed link
• 197  Marzano AV, Lazzari R, Polloni I, et al. Drug‐induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011;165:335–41. Cross Ref link Pubmed link
• 198  David‐Bajar KM, Bennion SD, DeSpain JD, et al. Clinical, histological and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol 1992;99:251–7. Cross Ref link Pubmed link
• 199  Bielsa I, Herrero C, Collado A, et al. Histopathologic findings in cutaneous lupus erythematosus. Arch Dermatol 1994;130:54–8. Cross Ref link Pubmed link
• 200  Nieboer C, Tak‐Diamand Z, Van Leeuwen‐Wallau HE. Dust‐like particles: a specific direct immunofluorescence pattern in subacute cutaneous lupus erythematosus. Br J Dermatol 1988;118:725–29. Cross Ref link Pubmed link
• 201  Jerdan MS, Hood AF, Moore GW, et al. Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 1990;126:52–5. Cross Ref link Pubmed link
• 202  Al‐Refu K, Goodfield M. Immunohistochemistry of ultrastructural changes in scarring lupus erythematosus. Clin Exp Dermatol 2011;36:63–8. Cross Ref link Pubmed link
• 203  Wenzel J, Henze S, Worenkamper E, et al. Role of the chemokine receptor CCR4 and its ligand thymus‐ and activation‐regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol 2005;124:1241–8. Cross Ref link Pubmed link
• 204  Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006;65:545–8. Cross Ref link Pubmed link
• 205  Sontheimer RD. Subacute cutaneous lupus: a 25 year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological and genetic findings. Autoimmun Rev 2005;4:253–63. Cross Ref link Pubmed link
• 206  Sontheimer RD, Stastny P, Gilliam JN. Human histocompatibility antigen associations in subacute cutaneous lupus erythematosus. J Clin Invest 1981;67:312–16. Cross Ref link Pubmed link
• 207  Millard TP, McGregor JM. Molecular genetics of cutaneous lupus erythematosus. Clin Exp Dermatol 2001;26:184–91. Cross Ref link Pubmed link
• 208  Johansson‐Stephansson E, Koskimies S, Partanen J, et al. Subacute cutaneous lupus erythematosus: genetic markers and clinical and immunological findings in patients. Arch Dermatol 1989;125:791–6. Cross Ref link Pubmed link
• 209  Boeckler P, Milea M, Meyer A, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005;152:265–70. Cross Ref link Pubmed link
• 210  Millard TP, Kondeatis E, Cox A, et al. A candidate gene analysis of three photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. Br J Dermatol 2001;145:229–36. Cross Ref link Pubmed link
• 211  Millard, TP, Ashton GHS, Kondeatis E, et al. Human Ro60 (SSA2) genomic organization and sequence alterations, examined in cutaneous lupus erythematosus. Br J Dermatol 2002;146:210–15. Cross Ref link Pubmed link
• 212  Dowdy MJ, Nigra TP, Barth WF. Subacute cutaneous lupus erythematosus during PUVA therapy for psoriasis: case report and review of the literature. Arthritis Rheum 1989;32:343–6. Cross Ref link Pubmed link
• 213  Balabanova MB, Botev IN, Michailova JI. Subacute cutaneous lupus induced by radiation therapy. Br J Dermatol 1997;137:648–9. Cross Ref link Pubmed link
• 214  Nousari HC, Kimyai‐Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon b‐1a. Lancet 1998;352:1825–6. Cross Ref link Pubmed link
• 215  Rockmann H, Feller G, Schadenforf D, et al. Subacute cutaneous lupus on the lines of Blaschko. Eur J Dermatol 2006;16:302–6. Pubmed link
• 216  Perera GK, Black MM, McGibbon DH. Bullous subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2004;29:265–7. Cross Ref link Pubmed link
• 217  Peitsch WK, Lorentz K, Goebeler M, et al. Subacute cutaneous lupus erythematosus with bullae associated with porphyria cutanea tarda. J Dtsch Dermatol Ges 2007;5:220–2. Cross Ref link Pubmed link
• 218  De Spain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol 1988;19:388–92. Cross Ref link Pubmed link
• 219  Marzano AV, Facchetti M, Alessi E. Poikilodermatous subacute cutaneous lupus erythematosus. Dermatol 2003;207:285–90. Cross Ref link
• 220  Kreft B, Marsch WC. Lupus erythematosus gyratum repens. Eur J Drmatol 2007;17:79–82.
• 221  Berti S, Moretti S, Lucin C, et al. Urticarial vasculitis and subacute cutaneous lupus erythematosus. Lupus 2005;14:489–92. Cross Ref link Pubmed link
• 222  Heymann WR, Manders SM, Gottlieb GJ, et al. Subacute cutaneous lupus erythematosus associated with chronic interstitial pneumonitis. Int J Dermatol 1995;34:354–6. Cross Ref link Pubmed link
• 223  De‐Silva BD, Plant W, Kemmett D. Subacute cutaneous lupus erythematosus and life‐threatening hypokalaemic tetraparesis: a rare complication. Br J Dermatol 2001;144:622–4. Cross Ref link Pubmed link
• 224  Schewach‐Millet M, Shapiro D, Ziv R, et al. Subacute cutaneous lupus erythematosus associated with breast carcinoma. J Am Acad Dermatol 1988;19:406–8. Cross Ref link Pubmed link
• 225  Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis 2000;66:183–8. Pubmed link
• 226  Ho C, Shumack SP, Morris D. Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma. Australas J Dermatol 2001;42:110–13. Cross Ref link Pubmed link
• 227  Castenet J, Taillan B, Lacour JP, et al. Subacute cutaneous lupus erythematosus associated with Hodgkin's disease. Clin Rheumatol 1995;14: 692–4. Cross Ref link Pubmed link
• 228  Brenner S, Golan H, Gat A, et al. Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung. Dermatology 1997;194:172–4. Cross Ref link Pubmed link
• 229  Vogt T, Coras B, Hafner C, et al. Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematosus. Lancet Oncol 2006;7:695–7. Cross Ref link Pubmed link
• 230  Chaudry SI, Murphy LA, White IR. Subacute cutaneous lupus: A paraneoplastic dermatosis. Clin Exp Dermatol 2005;30:655–8. Cross Ref link Pubmed link
• 231  Weinstein CL, Littlejohn GO, Thomson NM, et al. Severe visceral disease in subacute cutaneous lupus erythematosus. Arch Dermatol 1987;123:638–40. Cross Ref link Pubmed link
• 232  Prystowsky SD, Gilliam JN. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol. 1975;111:1448–52. Cross Ref link Pubmed link
• 233  Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet induced lupus erythematosus. Arthritis Rheum 2004;50:3045–8. Cross Ref link Pubmed link
• 234  Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996;34:830–6. Cross Ref link Pubmed link
• 235  Heath M, Raugi GJ. Evidence‐based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus. Adv Dermatol 2004;20:257–91. Pubmed link
• 236  Kreuter A, Gambichler T, Breukmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407–10. Cross Ref link Pubmed link
• 237  Tzung TY, Liu YS, Chang HW. Tacrolimus vs clobetasol proprionate in the treatment of facial lupus erythematosus: a randomized, double blind, bilateral comparison study. Br J Dermatol 2007;156:191–2. Cross Ref link Pubmed link
• 238  Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002;11:71–81. Cross Ref link Pubmed link
• 239  Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415–22. Cross Ref link Pubmed link
• 240  Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment‐resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189:425–7. Cross Ref link Pubmed link
• 241  Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial therapy. J Am Acad Dermatol 2000;42:983–7. Cross Ref link Pubmed link
• 242  Goldberg JW, Lidsky MD. Pulse methylprednisolone therapy for persistent subacute cutaneous lupus. Arthritis Rheum 1984;27:837–8. Cross Ref link Pubmed link
• 243  Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988;124:897–902. Cross Ref link Pubmed link
• 244  Newton RC, Jorizzo JL, Solomon AR, et al. Mechanism‐oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986;122:170–6. Cross Ref link Pubmed link
• 245  Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementaemia: response to dapsone therapy. J Am Acad Dermatol 1996;35:313–15. Cross Ref link Pubmed link
• 246  Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002;46:600–3. Cross Ref link Pubmed link
• 247  Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 pateints. Br J Dermatol 2005;153:157–62. Cross Ref link Pubmed link
• 248  Huber A, Tuting T, Bauer R, et al. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol 2006;155:861–2. Cross Ref link Pubmed link
• 249  Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in 16 consecutive patients. Br J Rheumatol 1997;36:353–9. Cross Ref link Pubmed link
• 250  Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimes. Am J Med 2005;118:246–50. Cross Ref link Pubmed link
• 251  Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 2004;20;11. Cross Ref link
• 252  Rudnicka L, Szymanska E, Walecka I, et al. Long‐term cefuroxime acetyl in subacute cutaneous lupus erythematosus: a report of three cases. Dermatology 2000;200:129–31. Cross Ref link Pubmed link
• 253  Schanz S, Ulmer A, Rassner G, et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002;147:174–8. Cross Ref link Pubmed link
• 254  Goodfield, MJD, Davison K Bowden K. Intravenous Immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus. J Dermatol Treat 2004;15:46–50. Cross Ref link
• 255  Kreuter A, Hyun J, Altmeyer P, et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Dermvenereol 2005;85:545–7.
• 256  Fautrel B, Foltz V, Frances C, et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumour necrosis factor a‐blocking agent: comment on the article by Pisetsky and the letter from Aringer. Arthritis Rheum 2002;46:1408–9. Cross Ref link Pubmed link

Systemic lupus erythematosus

• 257  Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7. Cross Ref link Pubmed link
• 258  Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86. Cross Ref link Pubmed link
• 259  Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551–8. Cross Ref link Pubmed link
• 260  Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983;42:529–32. Cross Ref link Pubmed link
• 261  Fernandez M, Alarcon GS, Calvo‐Alen J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57:576–84. Cross Ref link Pubmed link
• 262  Somers EC, Marder W, Cagnoli P, et al. Population‐based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance (MILES) Program. Arthritis Rheum 2014;66:369–78. Cross Ref link
• 263  Reveille JD, Bias WB, Winkelstein JA, Provost TT, Dorsch CA, Arnett FC. Familial systemic lupus erythematosus: immunogenetic studies in eight families. Medicine (Baltimore) 1983;62:21–35. Cross Ref link Pubmed link
• 264  Arnett FC, Shulman LE. Studies in familial systemic lupus erythematosus. Medicine (Baltimore) 1976;55:313–22. Cross Ref link Pubmed link
• 265  Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977. Arthritis Rheum 1985;28:80–6. Cross Ref link Pubmed link
• 266  Jonsson H, Nived O, Sturfelt G. The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus. J Rheumatol 1988;15:505–9. Pubmed link
• 267  Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11:352–6. Cross Ref link Pubmed link
• 268  Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010;19:119–29. Cross Ref link Pubmed link
• 269  Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701–38. Cross Ref link
• 270  Rowell NR. Laboratory abnormalities in the diagnosis and management of lupus erythematosus. Br J Dermatol 1971;84:210–16. Cross Ref link Pubmed link
• 271  Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001;28:1–23. Cross Ref link Pubmed link
• 272  Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348–62. Cross Ref link Pubmed link
• 273  Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens‐Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol 2012;166:575–600. Cross Ref link Pubmed link
• 274  Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev 2009;8:467–73. Cross Ref link Pubmed link
• 275  Synkowski DR, Provost TT. Characterization of the inflammatory infiltrate in lupus erythematosus lesions using monoclonal antibodies. J Rheumatol 1983;10:920–4. Pubmed link
• 276  Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus 2010;19:1020–8. Cross Ref link Pubmed link
• 277  Brinster NK, Nunley J, Pariser R, Horvath B. Nonbullous neutrophilic lupus erythematosus: a newly recognized variant of cutaneous lupus erythematosus. J Am Acad Dermatol 2012;66:92–7. Cross Ref link Pubmed link
• 278  Reich A, Marcinow K, Bialynicki‐Birula R. The lupus band test in systemic lupus erythematosus patients. Ther Clin Risk Manag 2011;7:27–32. Cross Ref link Pubmed link
• 279  Burnham TK, Neblett TR, Fine G. The application of the fluorescent antibody technic to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol 1963;41:451–6. Cross Ref link Pubmed link
• 280  Cormane RH. “Bound” globulin in the skin of patients with chronic discoid lupus erythematosus and systemic lupus erythematosus. Lancet 1964;1(7332):534–5. Cross Ref link Pubmed link
• 281  Rowell NR, Scott DG. Immunohistological studies, with anti‐connective tissue and anti‐immunoglobulin antisera, of the skin in lupus erythematosus and scleroderma. Br J Dermatol 1975;93:431–41. Cross Ref link Pubmed link
• 282  Davis BM, Gilliam JN. Prognostic significance of subepidermal immune deposits in uninvolved skin of patients with systemic lupus erythematosus: a 10‐year longitudinal study. J Invest Dermatol 1984;83:242–7. Cross Ref link Pubmed link
• 283  Chen ZY, Dobson RL, Ainsworth SK, Silver RM, Maricq HR. Epidermal nuclear immunofluorescence: serological correlations supporting an in vivo reaction. Br J Dermatol 1985;112:15–22. Cross Ref link Pubmed link
• 284  Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013;11:95. Cross Ref link Pubmed link
• 285  Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–50. Cross Ref link Pubmed link
• 286  Deng Y, Tsao BP. Genetics of human SLE. In: Wallace DJ, Hahn B, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:35–45. Cross Ref link
• 287  Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med 1975;59:533–52. Cross Ref link Pubmed link
• 288  Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560–6. Cross Ref link Pubmed link
• 289  Namjou B, Kothari PH, Kelly JA, et al. Evaluation of the TREX1 gene in a large multi‐ancestral lupus cohort. Genes Immun 2011;12:270–9. Cross Ref link Pubmed link
• 290  Lee‐Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3'‐5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065–7. Cross Ref link Pubmed link
• 291  Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell‐intrinsic initiation of autoimmunity. Cell 2008;134:587–98. Cross Ref link Pubmed link
• 292  Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013;72(Suppl. 2):ii56–61. Cross Ref link Pubmed link
• 293  Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLOS Genet 2008;4:e1000024. Cross Ref link Pubmed link
• 294  Reveille JD, Macleod MJ, Whittington K, Arnett FC. Specific amino acid residues in the second hypervariable region of HLA‐DQA1 and DQB1 chain genes promote the Ro (SS‐A)/La (SS‐B) autoantibody responses. J Immunol 1991;146:3871–6. Pubmed link
• 295  Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009;27:363–91. Cross Ref link Pubmed link
• 296  Franchin G, Zou Y‐R, Diamond B. The structure and derivation of antibodies and autoantibodies. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:76–95. Cross Ref link
• 297  Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013;368:1528–35. Cross Ref link Pubmed link
• 298  Celhar T, Magalhaes R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012;53(1‐3):58–77. Cross Ref link Pubmed link
• 299  Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010;69:1370–7. Cross Ref link Pubmed link
• 300  Mazel JA, El‐Sherif N, Buyon J, Boutjdir M. Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Circulation 1999;99:1914–18. Cross Ref link Pubmed link
• 301  Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726–32. Cross Ref link Pubmed link
• 302  Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110–21. Cross Ref link Pubmed link
• 303  Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394–9. Cross Ref link Pubmed link
• 304  Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti‐IFN‐alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;2009:374312. Pubmed link
• 305  Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008;58:1762–73. Cross Ref link Pubmed link
• 306  Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579–88. Cross Ref link Pubmed link
• 307  Linker‐Israeli M, Quismorio FP, Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216–25. Cross Ref link Pubmed link
• 308  Crispin JC, Tsokos GC. Transcriptional regulation of IL‐2 in health and autoimmunity. Autoimmun Rev 2009;8:190–5. Cross Ref link Pubmed link
• 309  Crispin JC, Liossis SN, Kis‐Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010;16:47–57. Cross Ref link Pubmed link
• 310  Zandman‐Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus‐related diseases. Lupus 2012;21:241–50. Cross Ref link Pubmed link
• 311  Cooper GS, Wither J, Bernatsky S, et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 2010;49:2172–80. Cross Ref link Pubmed link
• 312  Ekblom‐Kullberg S, Kautiainen H, Alha P, Leirisalo‐Repo M, Julkunen H. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol 2013;32:1219–22. Cross Ref link Pubmed link
• 313  Foering K, Chang AY, Piette EW, Cucchiara A, Okawa J, Werth VP. Characterization of clinical photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol 2013;69:205–13. Cross Ref link Pubmed link
• 314  Millard TP, Hawk JL, McGregor JM. Photosensitivity in lupus. Lupus 2000;9:3–10. Cross Ref link Pubmed link
• 315  Lehmann P, Holzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990;22(2 Pt 1):181–7. Cross Ref link Pubmed link
• 316  Gehrke N, Mertens C, Zillinger T, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING‐dependent immune sensing. Immunity 2013;39:482–95. Cross Ref link Pubmed link
• 317  James JA, Kaufman KM, Farris AD, Taylor‐Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein‐Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019–26. Cross Ref link Pubmed link
• 318  Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007;56:1251–62. Cross Ref link Pubmed link
• 319  McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta‐analysis. Arthritis Rheum 2003;48:2100–10. Cross Ref link Pubmed link
• 320  Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum 2005;52:3701–12. Cross Ref link Pubmed link
• 321  Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11:352–6. Cross Ref link Pubmed link
• 322  Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012;11(6/7):A465–70. Cross Ref link Pubmed link
• 323  Dalle Vedove C, Simon JC, Girolomoni G. Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFalpha agents. J Dtsch Dermatol Ges 2012;10:889–97. Pubmed link
• 324  Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug‐induced lupus erythematosus. Arch Dermatol Res 2009;301:99–105. Cross Ref link Pubmed link
• 325  Borchers AT, Keen CL, Gershwin ME. Drug‐induced lupus. Ann NY Acad Sci 2007;1108:166–82. Cross Ref link Pubmed link
• 326  Patel D, Richardson B. Drug‐induced lupus: etiology, pathogenesis and clinical aspects. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:484–94. Cross Ref link
• 327  Sim E, Gill EW, Sim RB. Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet 1984;2(8400):422–4. Cross Ref link Pubmed link
• 328  Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005;280:40749–56. Cross Ref link Pubmed link
• 329  Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine‐induced lupus. J Immunol 2007;179:5553–63. Cross Ref link Pubmed link
• 330  Mansilla‐Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. BMJ 1982;284(6320):936–9. Cross Ref link Pubmed link
• 331  Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996;132:934–9. Cross Ref link Pubmed link
• 332  Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007;157:540–6. Cross Ref link Pubmed link
• 333  Wetter DA, Davis MD. Lupus‐like syndrome attributable to anti‐tumor necrosis factor alpha therapy in 14 patients during an 8‐year period at Mayo Clinic. Mayo Clin Proc 2009;84:979–84. Cross Ref link Pubmed link
• 334  Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 1964;190:104–11. Cross Ref link Pubmed link
• 335  Grigor R, Edmonds J, Lewkonia R, et al. Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 1978;37:121–8. Cross Ref link Pubmed link
• 336  Harvey AM, Shulman LE, Tumulty PA, et al. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954;33:291–437. Cross Ref link Pubmed link
• 337  Larson DL. Systemic Lupus Erythematosus. London: Churchill, 1961.
• 338  Lee P, Urowitz MB, Bookman AA, et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1–32. Pubmed link
• 339  Fries JF HH. Systemic lupus erythematosus: a clinical analysis. J Invest Dermatol 1976;67:554–5.
• 340  Ropes MW. Systemic Lupus Erythematosus. Cambridge, MA: Harvard University Press, 1976.
• 341  Flower C, Hennis AJ, Hambleton IR, et al. Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken) 2012;64:1151–8. Pubmed link
• 342  Pamuk O, Akbay F, Donmez S, et al. The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers. Lupus 2013;22:1416–24. Cross Ref link Pubmed link
• 343  Hinojosa‐Azaola A, Sanchez‐Guerrero J. Overview and clinical presentation. In: Wallace DJ, Hahn BH, ed. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:304. Cross Ref link
• 344  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 345  Lu LJ, Wallace DJ, Ishimori ML, et al. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010;19:119–29. Cross Ref link Pubmed link
• 346  Tan TC, Fang H, Magder LS, et al. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol 2012;39:759–69. Cross Ref link Pubmed link
• 347  Andrade RM, Alarcon GS, Fernandez M, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum 2007;56:622–30. Cross Ref link Pubmed link
• 348  Resende AL, Titan SM, Barros RT, et al. Worse renal outcome of lupus nephritis in male patients: a case–control study. Lupus 2011;20:561–7. Cross Ref link Pubmed link
• 349  Schwartzman‐Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012;2012:604892. Pubmed link
• 350  Hinojosa‐Azaola A, Sanchez‐Guerrero J. Overview and clinical presentation. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:304. Cross Ref link
• 351  Font J, Cervera R, Ramos‐Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217–30. Cross Ref link Pubmed link
• 352  Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10‐year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299–308. Cross Ref link Pubmed link
• 353  Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population‐based study. Arch Dermatol 2009;145:249–53. Cross Ref link Pubmed link
• 354  Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1249–54. Cross Ref link Pubmed link
• 355  Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. computer analysis of 520 cases. JAMA 1964;190:104–11. Cross Ref link Pubmed link
• 356  Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun Rev 2008;7:235–9. Cross Ref link Pubmed link
• 357  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 358  Font J, Cervera R, Ramos‐Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217–30. Cross Ref link Pubmed link
• 359  Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348–62. Cross Ref link Pubmed link
• 360  Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996;135:355–62. Cross Ref link Pubmed link
• 361  Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4:471–5. Cross Ref link Pubmed link
• 362  Cardinali C, Caproni M, Bernacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus – the Italian experience. Lupus 2000;9:417–23. Cross Ref link Pubmed link
• 363  Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010;19:1050–70. Cross Ref link Pubmed link
• 364  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 365  Tuffanelli DL. Lupus erythematosus panniculitis (profundus). Arch Dermatol 1971;103:231–42. Cross Ref link Pubmed link
• 366  Diaz‐Jouanen E, DeHoratius RJ, Alarcon‐Segovia D, et al. Systemic lupus erythematosus presenting as panniculitis (lupus profundus). Ann Intern Med 1975;82:376–9. Cross Ref link Pubmed link
• 367  Braunstein I, Werth VP. Update on management of connective tissue panniculitides. Dermatol Ther 2012;25:173–82. Cross Ref link Pubmed link
• 368  Izumi AK, Takiguchi P. Lupus erythematosus panniculitis. Arch Dermatol 1983;119:61–4. Cross Ref link Pubmed link
• 369  Ng PP, Tan SH, Tan T. Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 2002;41:488–90. Cross Ref link Pubmed link
• 370  Sontheimer RD. Subacute cutaneous lupus erythematosus: 25‐year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005;4:253–63. Cross Ref link Pubmed link
• 371  Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348–62. Cross Ref link Pubmed link
• 372  Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10:365–81. Cross Ref link Pubmed link
• 373  Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996;135:355–62. Cross Ref link Pubmed link
• 374  Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012;2012:834291. Pubmed link
• 375  Rihner M, McGrath H, Jr. Fluorescent light photosensitivity in patients with systemic lupus erythematosus. Arthritis Rheum 1992;35:949–52. Cross Ref link Pubmed link
• 376  Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum 1995;38:1152–6. Cross Ref link Pubmed link
• 377  Klein RS, Sayre RM, Dowdy JC, et al. The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus. Autoimmun Rev 2009;8:320–4. Cross Ref link Pubmed link
• 378  Loescher A, Edmondson HD. Lupus erythematosus – a case of facial swelling. Br J Oral Maxillofac Surg 1988;26:129–32. Cross Ref link Pubmed link
• 379  Ting W, Stone MS, Racila D, et al. Toxic epidermal necrolysis‐like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan‐epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 2004;13:941–50. Cross Ref link Pubmed link
• 380  Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi‐Goutieres syndrome. Am J Hum Genet 2007;80:811–15. Cross Ref link Pubmed link
• 381  Pock L, Petrovska P, Becvar R, et al. Verrucous form of chilblain lupus erythematosus. J Eur Acad Dermatol Venereol 2001;15:448–51. Cross Ref link Pubmed link
• 382  Stetson DB, Ko JS, Heidmann T, et al. Trex1 prevents cell‐intrinsic initiation of autoimmunity. Cell 2008;134:587–98. Cross Ref link Pubmed link
• 383  Prendiville JS, Crow YJ. Blue (or purple) toes: chilblains or chilblain lupus‐like lesions are a manifestation of Aicardi‐Goutieres syndrome and familial chilblain lupus. J Am Acad Dermatol 2009;61:727–8. Cross Ref link Pubmed link
• 384  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 385  Chong BF, Werth VP. Skin disease in cutanous lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:319. Cross Ref link
• 386  Trueb RM. Involvement of scalp and nails in lupus erythematosus. Lupus 2010;19:1078–86. Cross Ref link Pubmed link
• 387  Vaughn RY, Bailey JP, Jr, Field RS, et al. Diffuse nail dyschromia in black patients with systemic lupus erythematosus. J Rheumatol 1990;17:640–3. Pubmed link
• 388  Sherber NS, Wigley FM, Scher RK. Autoimmune disorders: nail signs and therapeutic approaches. Dermatol Ther 2007;20:17–30. Cross Ref link Pubmed link
• 389  Cutolo M, Sulli A, Secchi ME, et al. Nailfold capillaroscopy is useful for the diagnosis and follow‐up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 2006;45(Suppl. 4):iv43–6. Cross Ref link Pubmed link
• 390  Chong BF, Werth VP. Skin disease in cutanous lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:319. Cross Ref link
• 391  Werth VP, Vera Kellat C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747.
• 392  Moghadam‐Kia S, Franks AG, Jr. Autoimmune disease and hair loss. Dermatol Clin 2013;31:75–91. Cross Ref link Pubmed link
• 393  Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol 1992;128:368–71. Cross Ref link Pubmed link
• 394  Trueb RM. Involvement of scalp and nails in lupus erythematosus. Lupus 2010;19:1078–86. Cross Ref link Pubmed link
• 395  Chong BF, Werth VP. Skin disease in cutanous lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:319. Cross Ref link
• 396  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 397  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 398  Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012;2012:834291. Pubmed link
• 399  Ramos‐Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006;85:95–104. Cross Ref link Pubmed link
• 400  Gronhagen CM, Gunnarsson I, Svenungsson E, et al. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus 2010;19:1187–94. Cross Ref link Pubmed link
• 401  Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348–62. Cross Ref link Pubmed link
• 402  Dubois EL, Arterberry JD. Gangrene as a manifestation of systemic lupus erythematosus. JAMA 1962;181:366–74. Cross Ref link Pubmed link
• 403  Bernatsky S, Pineau CA, Lee JL, et al. Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus. Lupus 2006;15:671–74. Cross Ref link Pubmed link
• 404  Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 2007;16:505–8. Cross Ref link Pubmed link
• 405  Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol 2004;22:121–4. Cross Ref link Pubmed link
• 406  Karassa FB, Ioannidis JP, Touloumi G, et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 2000;93:169–74. Cross Ref link
• 407  Ortega‐Hernandez OD, Agmon‐Levin N, Blank M, et al. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 2009;32:1–6. Cross Ref link Pubmed link
• 408  High WA, Aranda J, Patel SB, et al. Is Degos' disease a clinical and histological end point rather than a specific disease? J Am Acad Dermatol 2004;50:895–9. Cross Ref link Pubmed link
• 409  Sakr SH, Russell EB, Jasin HE. Systemic lupus erythematosus and calciphylaxis. J Rheumatol 2004;31:1851–3. Pubmed link
• 410  Chong BF, Werth VP. Skin disease in cutanous lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:319. Cross Ref link
• 411  Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996;135:355–62. Cross Ref link Pubmed link
• 412  Davis MD, Daoud MS, Kirby B, Gibson LE, Rogers RS, 3rd. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol 1998;38:899–905. Cross Ref link Pubmed link
• 413  Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004;34:182–6. Cross Ref link Pubmed link
• 414  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 415  Lowe L, Rapini RP, Golitz LE, Johnson TM. Papulonodular dermal mucinosis in lupus erythematosus. J Am Acad Dermatol 1992;27(2 Pt 2):312–15. Cross Ref link Pubmed link
• 416  Sonntag M, Lehmann P, Megahed M, Ruzicka T, Kuhn A. Papulonodular mucinosis associated with subacute cutaneous lupus erythematosus. Dermatology 2003;206:326–9. Cross Ref link Pubmed link
• 417  Kuhn A, Richter‐Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P. Lupus erythematosus tumidus – a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000;136:1033–41. Cross Ref link Pubmed link
• 418  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 419  Balin SJ, Wetter DA, Andersen LK, et al. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol 2012;148:455–62. Cross Ref link Pubmed link
• 420  Boulman N, Slobodin G, Rozenbaum M, et al. Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805–12. Cross Ref link Pubmed link
• 421  Hahn BH, Yardley JH, Stevens MB. “Rheumatoid” nodules in systemic lupus erythematosus. Ann Intern Med 1970;72:49–58. Cross Ref link Pubmed link
• 422  Schofield JK, Cerio R, Grice K. Systemic lupus erythematosus presenting with ‘rheumatoid nodules’. Clin Exp Dermatol 1992;17:53–5. Cross Ref link Pubmed link
• 423  Dubois EL, Friou GJ, Chandor S. Rheumatoid nodules and rheumatoid granulomas in systemic lupus erythematosus. JAMA 1972;220:515–18. Cross Ref link Pubmed link
• 424  Bywaters EG, Glynn LE, Zeldis A. Subcutaneous nodules of Still's disease. Ann Rheum Dis 1958;17:278–85. Cross Ref link Pubmed link
• 425  Jallouli M, Francès C, Piette JC, et al. Hydroxychloroquine‐induced pigmentation in patients with systemic lupus erythematosus: a case–control study. JAMA Dermatol 2013;149:935–40. Cross Ref link Pubmed link
• 426  Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993;100:S28–34. Cross Ref link
• 427  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al. eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 428  Chong BF, Werth VP. Skin disease in cutanous lupus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:319. Cross Ref link
• 429  Jolly M, Francis S, Sequeira W. Differential diagnosis and disease associations. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:541. Cross Ref link
• 430  Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012;2012:834291. Pubmed link
• 431  Yell JA, Allen J, Wojnarowska, F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995;132:921–8. Cross Ref link Pubmed link
• 432  Alahlafi AM, Wordsworth P, Wojnarowska F. The lupus band: do the autoantibodies target collagen VII? Br J Dermatol 2004;150:504–10. Cross Ref link Pubmed link
• 433  Perez‐Perez ME, Avalos‐Diaz E, Herrera‐Esparza R. Autoantibodies in Senear‐Usher syndrome: cross‐reactivity or multiple autoimmunity? Autoimmune Dis 2012;2012:296214. Pubmed link
• 434  Rosenbaum J, Trune DR, Bankhuizen A, et al. Ocular, aural and oral manifestations. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:393. Cross Ref link
• 435  Urman JD, Lowenstein MB, Abeles M, et al. Oral mucosal ulceration in systemic lupus erythematosus. Arthritis Rheum 1978;21:58–61. Cross Ref link Pubmed link
• 436  Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012;2012:834291. Pubmed link
• 437  Werth VP, Vera‐Kellet C, Dutz JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 438  Jonsson R, Heyden G, Westberg NG, et al. Oral mucosal lesions in systemic lupus erythematosus – a clinical, histopathological and immunopathological study. J Rheumatol 1984;11:38–42. Pubmed link
• 439  Lourenco SV, de Carvalho FR, Boggio P, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of the inflammatory infiltrate. J Cutan Pathol 2007;34:558–64. Cross Ref link Pubmed link
• 440  Schiodt M. Oral discoid lupus erythematosus. III. A histopathologic study of sixty‐six patients. Oral Surg Oral Med Oral Pathol 1984;57:281–93. Cross Ref link Pubmed link
• 441  Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006;24:348–62. Cross Ref link Pubmed link
• 442  Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10:365–81. Cross Ref link Pubmed link
• 443  Nico MM, Vilela MA, Rivitti EA, et al. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008;18:376–81. Pubmed link
• 444  Burge SM, Frith PA, Juniper RP, et al. Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. Br J Dermatol 1989;121:727–41. Cross Ref link Pubmed link
• 445  Liu W, Shen ZY, Wang LJ, et al. Malignant potential of oral and labial chronic discoid lupus erythematosus: a clinicopathological study of 87 cases. Histopathology 2011;59:292–8. Cross Ref link Pubmed link
• 446  Jolly M, Francis S, Sequeira W. Differential diagnosis and disease associations. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier, Saunders, 2013:541–54. Cross Ref link
• 447  McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 2000;59:230–2. Cross Ref link Pubmed link
• 448  Solomon DH, Kavanaugh AJ, Schur PH. Evidence‐based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434–44. Cross Ref link Pubmed link
• 449  Alarcon GS, McGwin G, Jr, Roseman JM, et al. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum 2004;51:609–15. Cross Ref link Pubmed link
• 450  Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344–51. Cross Ref link Pubmed link
• 451  Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000;124:71–81. Pubmed link
• 452  Maddison PJ, Provost TT, Reichlin M. Serological findings in patients with “ANA‐negative” systemic lupus erythematosus. Medicine (Baltimore) 1981;60:87–94. Cross Ref link Pubmed link
• 453  Hanly JG, Thompson K, McCurdy G, Fougere L, Theriault C, Wilton K. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus. J Immunol Methods 2010;352(1/2):147–52. Cross Ref link Pubmed link
• 454  Williams RE, Mackie RM, O'Keefe R, Thomson W. The contribution of direct immunofluorescence to the diagnosis of lupus erythematosus. J Cutan Pathol 1989;16:122–5. Cross Ref link Pubmed link
• 455  Labowitz R, Schumacher HR, Jr. Articular manifestations of systemic lupus erythematosus. Ann Intern Med 1971;74:911–21. Cross Ref link Pubmed link
• 456  Navarra S, Torralba T. The musculoskeletal system and bone metabolism. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 457  Fernandez A, Quintana G, Matteson EL, et al. Lupus arthropathy: historical evolution from deforming arthritis to rhupus. Clin Rheumatol 2004;23:523–6. Cross Ref link Pubmed link
• 458  Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti‐cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol 2008;35:77–83. Pubmed link
• 459  Esdaile JM, Danoff D, Rosenthall L, Gutkowski A. Deforming arthritis in systemic lupus erythematosus. Ann Rheum Dis 1981;40:124–6. Cross Ref link Pubmed link
• 460  Van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998;57:540–4. Cross Ref link Pubmed link
• 461  Potasman I, Bassan HM. Multiple tendon rupture in systemic lupus erythematosus: case report and review of the literature. Ann Rheum Dis 1984;43:347–9. Cross Ref link Pubmed link
• 462  Isenberg DA, Snaith ML. Muscle disease in systemic lupus erythematosus: a study of its nature, frequency and cause. J Rheumatol 1981;8:917–24. Pubmed link
• 463  Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998;37:895–900. Cross Ref link Pubmed link
• 464  Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47‐year perspective. Am J Orthop 1998;27:352–4. Pubmed link
• 465  Klipper AR, Stevens MB, Zizic TM, Hungerford DS. Ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 1976;55:251–7. Cross Ref link Pubmed link
• 466  Halland AM, Klemp P, Botes D, Van Heerden BB, Loxton A, Scher AT. Avascular necrosis of the hip in systemic lupus erythematosus: the role of magnetic resonance imaging. Br J Rheumatol 1993;32:972–6. Cross Ref link Pubmed link
• 467  Hungerford DS, Zizic TM. II: The treatment of ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 1980;59:143–8. Cross Ref link Pubmed link
• 468  Lane NE. Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006;2:562–9. Cross Ref link Pubmed link
• 469  Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 2014;40:51–60. Cross Ref link Pubmed link
• 470  Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10‐year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299–308. Cross Ref link Pubmed link
• 471  Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988;85:645–50. Cross Ref link Pubmed link
• 472  Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985;55:87–98. Pubmed link
• 473  Manzi S, Meilahn EN, Rairie JE, et al. Age‐specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15. Cross Ref link Pubmed link
• 474  Karp I, Abrahamowicz M, Fortin PR, et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008;59:169–75. Cross Ref link Pubmed link
• 475  Apte M, McGwin G, Jr, Vila LM, Kaslow RA, Alarcon GS, Reveille JD. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV) [Corrected]. Rheumatology (Oxford) 2008;47:3627.
• 476  Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007;28:441–50. Cross Ref link Pubmed link
• 477  Ruiz‐Irastorza G, Khamashta M. Cardiopulmonary disease in SLE. In: Wallace D, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:352–62. Cross Ref link
• 478  Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 2010;31:479–88. Cross Ref link Pubmed link
• 479  Onomura K, Nakata H, Tanaka Y, Tsuda T. Pulmonary hemorrhage in patients with systemic lupus erythematosus. J Thorac Imaging 1991;6:57–61. Cross Ref link Pubmed link
• 480  Rubin LA, Urowitz MB. Shrinking lung syndrome in SLE – a clinical pathologic study. J Rheumatol 1983;10:973–6. Pubmed link
• 481  Karim MY, Miranda LC, Tench CM, et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002;31:289–98. Cross Ref link Pubmed link
• 482  Dooley MA. Clinical and epidemiologic features of lupus nephritis. In: Wallace D, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelpia, PA: Elsevier Saunders, 2013:438–54. Cross Ref link
• 483  Sauter M, Anders HJ. Lupus nephritis. Minerva Med 2007;98:749–58. Pubmed link
• 484  Adelman DC, Wallace DJ, Klinenberg JR. Thirty‐four‐year delayed‐onset lupus nephritis: a case report. Arthritis Rheum 1987;30:479–80. Cross Ref link Pubmed link
• 485  Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011;45:436–41. Cross Ref link Pubmed link
• 486  Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:917–32. Cross Ref link Pubmed link
• 487  Ramirez‐Mata M, Reyes PA, Alarcon‐Segovia D, Garza R. Esophageal motility in systemic lupus erythematosus. Am J Dig Dis 1974;19:132–6. Cross Ref link Pubmed link
• 488  Marino C, Lipstein‐Kresch E. Pancreatitis in systemic lupus erythematosus. Arthritis Rheum 1984;27:118–19. Cross Ref link Pubmed link
• 489  Campos LM, Omori CH, Lotito AP, Jesus AA, Porta G, Silva CA. Acute pancreatitis in juvenile systemic lupus erythematosus: a manifestation of macrophage activation syndrome? Lupus 2010;19:1654–8. Cross Ref link Pubmed link
• 490  Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 2005;14:822–6. Cross Ref link Pubmed link
• 491  Leggett BA. The liver in systemic lupus erythematosus. J Gastroenterol Hepatol 1993;8:84–8. Cross Ref link Pubmed link
• 492  Ohira H, Takiguchi J, Rai T, et al. High frequency of anti‐ribosomal P antibody in patients with systemic lupus erythematosus‐associated hepatitis. Hepatol Res 2004;28:137–9. Cross Ref link Pubmed link
• 493  Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–76. Cross Ref link Pubmed link
• 494  Hall S, Czaja AJ, Kaufman DK, Markowitz H, Ginsburg WW. How lupoid is lupoid hepatitis? J Rheumatol 1986;13:95–8. Pubmed link
• 495  Miller FW, Moore GF, Weintraub BD, Steinberg AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis Rheum 1987;30:1124–31. Cross Ref link Pubmed link
• 496  Hanly JG, Omisade A, Fisk JD. Psychopathology, neurodiagnostic testing and imaging. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:382–92. Cross Ref link
• 497  Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074–82. Cross Ref link Pubmed link
• 498  Anon. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608. Cross Ref link Pubmed link
• 499  Rhiannon JJ. Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management. Clin Rev Allergy Immunol 2008;34:356–60. Cross Ref link Pubmed link
• 500  Castellino G, Govoni M, Giacuzzo S, Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev 2008;7:297–304. Cross Ref link Pubmed link
• 501  Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008;58:843–53. Cross Ref link Pubmed link
• 502  Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti‐ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta‐analysis. Arthritis Rheum 2006;54:312–24. Cross Ref link Pubmed link
• 503  Rosenbaum J, Trune DR, Bankhuizen A, et al. Ocular, aural and oral manifestations. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:393. Cross Ref link
• 504  Lessell S. Some ophthalmological and neurological aspects of systemic lupus erythematosus. J Rheumatol 1980;7:398–404. Pubmed link
• 505  Wong K, Ai E, Jones JV, Young D. Visual loss as the initial symptom of systemic lupus erythematosus. Am J Ophthalmol 1981;92:238–44. Cross Ref link Pubmed link
• 506  Stafford‐Brady FJ, Urowitz MB, Gladman DD, et al. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 1988;31:1105–10. Cross Ref link Pubmed link
• 507  Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972;56:800–4. Cross Ref link Pubmed link
• 508  Naarendorp M, Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus‐like syndromes and antiphospholipid antibodies. J Rheumatol 1998;25:589–92. Pubmed link
• 509  Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood‐onset lupus and adult‐onset lupus: a meta‐analysis. Lupus 2011;20:1345–55. Cross Ref link Pubmed link
• 510  Klein‐Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am 2002;28:561–77, vi–vii. Cross Ref link Pubmed link
• 511  Meislin AG, Rothfield N. Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 1968;42:37–49. Pubmed link
• 512  Livingston B, Bonner A, Pope J. Differences in autoantibody profiles and disease activity and damage scores between childhood‐ and adult‐onset systemic lupus erythematosus: a meta‐analysis. Semin Arthritis Rheum 2012;42:271–80. Cross Ref link Pubmed link
• 513  Lee PY, Yeh KW, Yao TC, et al. The outcome of patients with renal involvement in pediatric‐onset systemic lupus erythematosus – a 20‐year experience in Asia. Lupus 2013;22:1534–40. Cross Ref link Pubmed link
• 514  Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood‐onset and adult‐onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556–62. Cross Ref link Pubmed link
• 515  Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021–8. Cross Ref link Pubmed link
• 516  Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood‐onset lupus and adult‐onset lupus: a meta‐analysis. Lupus 2011;20:1345–55. Cross Ref link Pubmed link
• 517  Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun Rev 2008;7:235–9. Cross Ref link Pubmed link
• 518  Lalani S, Pope J, de Leon F, Peschken C, Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of late‐onset systemic lupus erythematosus: results from the 1000 Faces of Lupus study. J Rheumatol 2010;37:38–44. Cross Ref link Pubmed link
• 519  Clowse MEB. Pregnancy in women with SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:455. Cross Ref link
• 520  Chakravarty EF. Reproductive and hormonal issues in women with autoimmune diseases. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:473. Cross Ref link
• 521  Meehan RT, Dorsey JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 1987;14:252–8. Pubmed link
• 522  Hayslett JP. Effect of pregnancy in patients with SLE. Am J Kidney Dis 1982;2(1 Suppl. 1):223–8. Pubmed link
• 523  Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003;16:161–7. Pubmed link
• 524  Rahman FZ, Rahman J, Al‐Suleiman SA, et al. Pregnancy outcome in lupus nephropathy. Arch Gynecol Obstet 2005;271:222–6. Cross Ref link Pubmed link
• 525  Julkunen H, Kaaja R, Palosuo T, et al. Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand 1993;72:258–63. Cross Ref link Pubmed link
• 526  Huong DL, Wechsler B, Vauthier‐Brouzes D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 2001;60:599–604. Cross Ref link Pubmed link
• 527  Clark CA, Spitzer KA, Nadler JN, et al. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127–32. Pubmed link
• 528  Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta‐analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060–8. Cross Ref link Pubmed link
• 529  Grennan DM, McCormick JN, Wojtacha D, et al. Immunological studies of the placenta in systemic lupus erythematosus. Ann Rheum Dis 1978;37:129–34. Cross Ref link Pubmed link
• 530  Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306. Cross Ref link Pubmed link
• 531  Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–4. Pubmed link
• 532  Empson M, Lassere M, Craig JC, et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135–44. Pubmed link
• 533  Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004;50:1028–39. Cross Ref link Pubmed link
• 534  Park‐Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta‐analysis of epidemiological studies. Teratology 2000;62:385–92. Cross Ref link Pubmed link
• 535  Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther 2013;26:354–63. Cross Ref link Pubmed link
• 536  Ostensen M, Khamashta M, Lockshin M, et al. Anti‐inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209. Cross Ref link Pubmed link
• 537  Fischer‐Betz R, Specker C, Brinks R, et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013;52:1070–6. Cross Ref link Pubmed link
• 538  Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640–7. Cross Ref link Pubmed link
• 539  Izmirly PM, Costedoat‐Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti‐SSA/Ro‐antibody‐associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76–82. Cross Ref link Pubmed link
• 540  Lateef A, Petri M. Hormone replacement and contraceptive therapy in autoimmune diseases. J Autoimmun 2012;38(2/3):J170–6. Cross Ref link Pubmed link
• 541  Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Surv 2011;66:639–53. Cross Ref link Pubmed link
• 542  Werth VP, Vera‐Kellet C, Dutz JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 543  Amezcua‐Guerra LM, Springall R, Marquez‐Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with ‘rhupus’: a cross‐sectional study. Arthritis Res Ther 2006;8:R144. Cross Ref link Pubmed link
• 544  Simon JA, Granados J, Cabiedes J, et al. Clinical and immunogenetic characterization of Mexican patients with ‘rhupus’. Lupus 2002;11:287–92. Cross Ref link Pubmed link
• 545  Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon‐mediated continuum. Arthritis Rheum 2010;62:589–98. Cross Ref link Pubmed link
• 546  Mackel SE, Kozin F, Ryan LM, et al. Concurrent linear scleroderma and systemic lupus erythematosus: a report of two cases. J Invest Dermatol 1979;73:368–72. Cross Ref link Pubmed link
• 547  Mitchell AJ, Rusin LJ, Diaz LA. Circumscribed scleroderma with immunologic evidence of systemic lupus erythematosus. Arch Dermatol 1980;116:69–73. Cross Ref link Pubmed link
• 548  Bootsma H, Bouma H, Kroese FGM, et al. Management of Sjogren syndrome in patients with SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:401. Cross Ref link
• 549  Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 2004;50:882–91. Cross Ref link Pubmed link
• 550  Masatlioglu SP, Goktay F, Mansur AT, et al. Systemic lupus erythematosus presenting as pyoderma gangrenosum in two cases. Rheumatol Int 2009;29:837–40. Cross Ref link Pubmed link
• 551  Satter EK, High WA. Non‐bullous neutrophilic dermatosis within neonatal lupus erythematosus. J Cutan Pathol 2007;34:958–60. Cross Ref link Pubmed link
• 552  Barr KL, O'Connell F, Wesson S, et al. Nonbullous neutrophilic dermatosis: Sweet's syndrome, neonatal lupus erythematosus, or both? Mod Rheumatol 2009;19:212–15. Cross Ref link Pubmed link
• 553  Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994;130:1278–83. Cross Ref link Pubmed link
• 554  Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds. Report of 6 cases and a literature review. Dermatology 2008;216:305–11. Cross Ref link Pubmed link
• 555  Antille C, Frei M, Sorg O, et al. Amicrobial pustulosis of the folds associated with auto‐immune disorders. A case report with an analysis of cytokine expression profile in skin lesions of cutaneous neutrophilic lupus. Dermatology 2008;216:324–9. Cross Ref link Pubmed link
• 556  Hamilton DV. Systemic lupus erythematosus in a patient with Hashimoto's thyroiditis and pernicious anaemia. J R Soc Med 1978;71:147–9. Pubmed link
• 557  Hall S, Axelsen PH, Larson DE, et al. Systemic lupus erythematosus developing in patients with primary biliary cirrhosis. Ann Intern Med 1984;100:388–9. Cross Ref link Pubmed link
• 558  Lorber M, Gershwin ME, Shoenfeld Y. The coexistence of systemic lupus erythematosus with other autoimmune diseases: the kaleidoscope of autoimmunity. Semin Arthritis Rheum 1994;24:105–13. Cross Ref link Pubmed link
• 559  Dowdy MJ, Nigra TP, Barth WF. Subacute cutaneous lupus erythematosus during PUVA therapy for psoriasis: case report and review of the literature. Arthritis Rheum 1989;32:343–6. Cross Ref link Pubmed link
• 560  Lanzon AE, Navarra SV. Gigantomastia in a patient with systemic lupus erythematosus successfully treated by reduction mammoplasty. Lupus 2009;18:1309–12. Cross Ref link Pubmed link
• 561  Schwendiman MN, Beachkofsky TM, Wisco OJ, et al. Primary cutaneous nodular amyloidosis: case report and review of the literature. Cutis 2009;84:87–92. Pubmed link
• 562  Weinberg I, Vasiliev L, Gotsman I. Anti‐dsDNA antibodies in sarcoidosis. Semin Arthritis Rheum 2000;29:328–31. Cross Ref link Pubmed link
• 563  Kravitz P. Dermatofibromas and systemic lupus erythematosus. Arch Dermatol 1980;116:1347. Cross Ref link Pubmed link
• 564  Bernatsky S, Ramsey‐Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2014;73:138–42. Cross Ref link Pubmed link
• 565  Parikh‐Patel A, White RH, Allen M, et al. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008;19:887–94. Cross Ref link Pubmed link
• 566  Atwater AR, Longley BJ, Aughenbaugh WD. Kikuchi's disease: case report and systematic review of cutaneous and histopathologic presentations. J Am Acad Dermatol 2008;59:130–6. Cross Ref link Pubmed link
• 567  Kim JH, Kim YB, In SI, et al. The cutaneous lesions of Kikuchi's disease: a comprehensive analysis of 16 cases based on the clinicopathologic, immunohistochemical, and immunofluorescence studies with an emphasis on the differential diagnosis. Hum Pathol 2010;41:1245–54. Cross Ref link Pubmed link
• 568  Dorfman RF. Histiocytic necrotizing lymphadenitis of Kikuchi and Fujimoto. Arch Pathol Lab Med 1987;111:1026–9. Pubmed link
• 569  Seong GM, Kim JH, Lim GC, et al. Clinicopathological review of immunohistochemically defined Kikuchi‐Fujimoto disease – including some interesting cases. Clin Rheumatol 2012;31:1463–9. Cross Ref link Pubmed link
• 570  Rivano MT, Falini B, Stein H, et al. Histiocytic necrotizing lymphadenitis without granulocytic infiltration (Kikuchi's lymphadenitis). Morphological and immunohistochemical study of eight cases. Histopathology 1987;11:1013–27. Cross Ref link Pubmed link
• 571  Chan JK, Wong KC, Ng CS. A fatal case of multicentric Kikuchi's histiocytic necrotizing lymphadenitis. Cancer 1989;63:1856–62. Cross Ref link Pubmed link
• 572  Kuo TT. Kikuchi's disease (histiocytic necrotizing lymphadenitis). A clinicopathologic study of 79 cases with an analysis of histologic subtypes, immunohistology, and DNA ploidy. Am J Surg Pathol 1995;19:798–809. Cross Ref link Pubmed link
• 573  Hoffmann A, Kirn E, Kuerten A, et al. Active human herpesvirus‐6 (HHV‐6) infection associated with Kikuchi‐Fujimoto disease and systemic lupus erythematosus (SLE). In Vivo 1991;5:265–9. Pubmed link
• 574  Meyer O, Ribard P, Belmatoug N, et al. Three cases of Kituchi's lymphadenitis in systemic lupus erythematosus. Role of the parvovirus B19. Ann Med Interne (Paris) 1991;142:259–64. Pubmed link
• 575  Harris VK, Danda D, Murali NS, et al. Unusual association of Kikuchi's disease and dengue virus infection evolving into systemic lupus erythematosus. J Indian Med Assoc 2000;98:391–3. Pubmed link
• 576  Bataille V, Harland CC, Behrens J, et al. Kikuchi disease (histiocytic necrotizing lymphadenitis) in association with HTLV1. Br J Dermatol 1997;136:610–12. Cross Ref link Pubmed link
• 577  Bernatsky S, Levy D, Ramsey‐Goldman R, Gordon C, Rahman A, Clarke A. Mortality in SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia: Elsevier Saunders, 2013:666–75. Cross Ref link
• 578  Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7. Cross Ref link Pubmed link
• 579  Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:447–54. Cross Ref link Pubmed link
• 580  Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985;12:916–18. Pubmed link
• 581  Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:455–60. Cross Ref link Pubmed link
• 582  Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987;14(Suppl. 13):223–6. Pubmed link
• 583  Wilson HA, Hamilton ME, Spyker DA, et al. Age influences the clinical and serologic expression of systemic lupus erythematosus. Arthritis Rheum 1981;24:1230–5. Cross Ref link Pubmed link
• 584  Werth VP, Vera‐Kellet C, Dutz, JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 585  Quismorio FP, Jr, Torralba KD. Clinical applications and serologic tests, serum protein abnormalities and other clinical laboratory tests in SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:526. Cross Ref link
• 586  Manson J. Autoantibodies: antibody structure, function and production. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:273.
• 587  Karpouzas GA. Haematological and lymphoid abnormalities in SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:426. Cross Ref link
• 588  Fabre VC, Lear S, Reichlin M, et al. Twenty percent of biopsy specimens from sun‐exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol 1991;127:1006–11. Cross Ref link Pubmed link
• 589  Nitsche A, Taborda GD, Bouveta HM, et al. Pure red cell aplasia in a patient with systemic lupus erythematosus. J Rheumatol 1988;15:1012–13. Pubmed link
• 590  Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty‐six cases and literature review. Arthritis Rheum 2003;49:633–9. Cross Ref link Pubmed link
• 591  Rivero SJ, Diaz‐Jouanen E, Alarcon‐Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978;21:295–305. Cross Ref link Pubmed link
• 592  Ziakas PD, Giannouli S, Zintzaras E, et al. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366–9. Cross Ref link Pubmed link
• 593  Dillon AM, Stein HB, English RA. Splenic atrophy in systemic lupus erythematosus. Ann Intern Med 1982;96:40–3. Cross Ref link Pubmed link
• 594  Shore RN, Faricelli JA. Borderline and reactive FTA‐ABS. Results in lupus erythematosus. Arch Dermatol 1977;113:37–41. Cross Ref link Pubmed link
• 595  Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010;12:70–6. Cross Ref link Pubmed link
• 596  Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 2000;93:169–74. Cross Ref link
• 597  Arnson Y, Shoenfeld Y, Alon E, et al. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010;40:97–108. Cross Ref link Pubmed link
• 598  Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the LE. cell. Proc Staff Meet Mayo Clin 1948;23:25–8. Pubmed link
• 599  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 600  Condemi J, Blomgren S, Vaughan JH. Procaineamide induced LE. Bull Rheum Dis 1970:604. Pubmed link
• 601  Beck JS. Auto‐antibodies to cell nuclei. Scott Med J 1963;8:373–88. Pubmed link
• 602  Casals SP, Friou GJ, Teague PO. Specific nuclear reaction pattern of antibody to DNA in lupus erythematosus sera. J Lab Clin Med 1963;62:625–31. Pubmed link
• 603  Nisengard RJ, Jablonska S, Chorzelski TP, et al. Diagnosis of systemic lupus erythematosus. Importance of antinuclear antibody titers and peripheral staining patterns. Arch Dermatol 1975;111:1298–300. Cross Ref link Pubmed link
• 604  Burnham TK. Antinuclear antibodies. II. The prognostic significance of nuclear immunofluorescent patterns in lupus erythematosus. Arch Dermatol 1975;111:203–7. Cross Ref link Pubmed link
• 605  Mandl MA, Watson JI. Nuclear immunofluorescence: a guide to treatment in SLE. Lancet 1969;2(7625):848. Cross Ref link Pubmed link
• 606  Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33. Cross Ref link Pubmed link
• 607  Rowell NR, Beck JS. The diagnostic value of an antinuclear antibody test in clinical dermatology. Arch Dermatol 1967;96:290–5. Cross Ref link Pubmed link
• 608  Bernstein RM, Steigerwald JC, Tan EM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982;48:43–51. Pubmed link
• 609  Ballou SP, Kushner I. Lupus patients who lack detectable anti‐DNA: clinical features and survival. Arthritis Rheum 1982;25:1126–9. Cross Ref link Pubmed link
• 610  Hughes GRV. Lupus erythematosus. In: Walker G, ed. Symposium of Advanced Medicine, 9th edn. London: Pitman, 1973:67.
• 611  Lindstedt G, Lundberg PA, Westberg G, et al. SLE nephritis with positive tests for antibodies against native DNA but negative tests for antinuclear antibodies. Lancet 1977;2(8029):135. Cross Ref link Pubmed link
• 612  Weinstein A, Bordwell B, Stone B, et al. Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983;74:206–16. Cross Ref link Pubmed link
• 613  Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence‐based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434–44. Cross Ref link Pubmed link
• 614  Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269–74. Cross Ref link Pubmed link
• 615  Petri MA, van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143–53. Cross Ref link Pubmed link
• 616  Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012;64:511–18. Cross Ref link Pubmed link
• 617  Agarwal S, Harper J, Kiely PD. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009;18:407–12. Cross Ref link Pubmed link
• 618  Arnett FC, Hamilton RG, Roebber MG, et al. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 1988;15:1773–76. Pubmed link
• 619  Benito‐Garcia E, Schur PH, Lahita R. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti‐Sm and anti‐RNP antibody tests. Arthritis Rheum 2004;51:1030–44. Cross Ref link Pubmed link
• 620  Ben‐Chetrit E, Fox RI, Tan EM. Dissociation of immune responses to the SS‐A (Ro) 52‐kD and 60‐kD polypeptides in systemic lupus erythematosus and Sjogren's syndrome. Arthritis Rheum 1990;33:349–55. Cross Ref link Pubmed link
• 621  Rowell NR, Beck JS, Anderson JR. Lupus erythematosus and erythema multiforme‐like lesions. A syndrome with characteristic immunological abnormalities. Arch Dermatol 1963;88:176–80. Cross Ref link Pubmed link
• 622  Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006;15:422–7. Cross Ref link Pubmed link
• 623  Perek J, Mittelman M, Eisbruch A, et al. Systemic lupus erythematosus preceded by long‐term cryoglobulinaemia. Ann Rheum Dis 1984;43:339–40. Cross Ref link Pubmed link
• 624  Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533–8. Cross Ref link Pubmed link
• 625  Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227–324. Cross Ref link Pubmed link
• 626  Steinsson K, McLean RH, Merrow M, et al. Selective complete Clq deficiency associated with systemic lupus erythematosus. J Rheumatol 1983;10:590–94. Pubmed link
• 627  Lipsker D, Hauptmann G. Cutaneous manifestations of complement deficiencies. Lupus 2010;19:1096–106. Cross Ref link Pubmed link
• 628  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 629  Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420–2. Cross Ref link Pubmed link
• 630  Koller SR, Johnston CL, Jr, Moncure CW. Lupus erythematosus cell preparation–antinuclear factor incongruity. A review of diagnostic tests for systemic lupus erythematosus. Am J Clin Pathol 1976;66:495–505. Cross Ref link Pubmed link
• 631  Maddison PJ, Provost TT, Reichlin M. Serological findings in patients with “ANA‐negative” systemic lupus erythematosus. Medicine (Baltimore) 1981;60:87–94. Cross Ref link Pubmed link
• 632  Reichlin M. Diagnostic criteria and serology. In: Schur P, ed. Clinical Management of Systemic Lupus Erythematosus. New York: Grune and Stratton, 1983.
• 633  Quismorio FP, Jr, Torralba KD. Clinical applications and serologic tests, serum protein abnormalities and other clinical laboratory tests in SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:526. Cross Ref link
• 634  Visentini M, Conti V, Cagliuso M, et al. Regression of systemic lupus erythematosus after development of an acquired Toll‐like receptor signaling defect and antibody deficiency. Arthritis Rheum 2009;60:2767–71. Cross Ref link Pubmed link
• 635  Werth VP, Vera‐Kellet C, Dutz JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 636  Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2014;10:97–107. Cross Ref link Pubmed link
• 637  Manzi S, Kao AH. Systemic lupus erythematosus: treatment and assessment. In: Stone, JH, Crofford LJ, White PH, eds. Primer on the Rheumatic Diseases, 13th edn. New York: Springer, 2008:327–38.
• 638  Werth VP, Vera‐Kellet C, Dutz JP. Skin. In: Lahita RG, Tsokos G, Buyon JP, et al., eds. Systemic Lupus Erythematosus, 5th edn. Oxford: Elsevier, 2011:747. Cross Ref link
• 639  Ishimari M, Weisman MH, Setoodeh K, et al. Principles of therapy, local measures and nonsteroidal medications. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Saunders Elsevier, 2013:582. Cross Ref link
• 640  Formica MK, Palmer JR, Rosenberg L, et al. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003;30:1222–6. Pubmed link
• 641  Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70–5. Pubmed link
• 642  Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009;61:1396–402. Cross Ref link Pubmed link
• 643  Holick MF. Vitamin D: a d‐lightful solution for health. J Investig Med 2011;59:872–80. Pubmed link
• 644  Singh A, Kamen DL. Potential benefits of vitamin D for patients with systemic lupus erythematosus. Dermatoendocrinology 2012;4:146–51. Cross Ref link
• 645  Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81. Cross Ref link Pubmed link
• 646  Rowell NR. Laboratory abnormalities in the diagnosis and management of lupus erythematosus. Br J Dermatol 1971;84:210–16. Cross Ref link Pubmed link
• 647  Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti‐dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359–66. Cross Ref link Pubmed link
• 648  Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012;64:511–18. Cross Ref link Pubmed link
• 649  Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269–74. Cross Ref link Pubmed link
• 650  Lightfoot RW, Jr, Hughes GR. Significance of persisting serologic abnormalities in SLE. Arthritis Rheum 1976;19:837–43. Cross Ref link Pubmed link
• 651  Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study. Br J Dermatol 2007;156:191–2. Cross Ref link Pubmed link
• 652  Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. J Am Acad Dermatol 2011;65:54–64, 64.e1–2. Cross Ref link Pubmed link
• 653  Barikbin B, Givrad S, Yousefi M, et al. Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clin Exp Dermatol 2009;34:776–80. Cross Ref link Pubmed link
• 654  Ruiz‐Irastorza G, Ramos‐Casals M, Brito‐Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20–8. Cross Ref link Pubmed link
• 655  Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013;15:360. Cross Ref link Pubmed link
• 656  Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA‐EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82. Cross Ref link Pubmed link
• 657  Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808. Cross Ref link Pubmed link
• 658  Anon. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785–96. Cross Ref link Pubmed link
• 659  Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007;16:387–93. Cross Ref link Pubmed link
• 660  Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001;10:140–7. Cross Ref link Pubmed link
• 661  Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560–4. Cross Ref link Pubmed link
• 662  Ackerman GL, Nolsn CM. Adrenocortical responsiveness after alternate‐day corticosteroid therapy. N Engl J Med 1968;278:405–9. Cross Ref link Pubmed link
• 663  Kirou KA, Boumpas DT. Systemic glucocorticoid therapy in SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:591. Cross Ref link
• 664  McCune WJ, Gonzalez‐Rivera T. Immunosuppressive drug therapy. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:609. Cross Ref link
• 665  Dooley MA. Clinical and epidemiologic features of lupus nephritis. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013:438. Cross Ref link
• 666  Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971–80. Cross Ref link Pubmed link
• 667  Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886–95. Cross Ref link Pubmed link
• 668  Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103–12. Cross Ref link Pubmed link
• 669  Werth V, Franks A, Jr. Treatment of discoid skin lesions with azathioprine. Arch Dermatol 1986;122:746–7. Cross Ref link Pubmed link
• 670  Callen JP, Spencer LV, Burruss JB, et al. Azathioprine. An effective, corticosteroid‐sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127:515–22. Cross Ref link Pubmed link
• 671  Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus and Related Syndromes, 8th edn. Philadelphia, PA: Elsevier Saunders, 2013.
• 672  Ginzler EM, Wofsy D, Isenberg D, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open‐label, parallel‐group clinical trial. Arthritis Rheum 2010;62:211–21. Cross Ref link Pubmed link
• 673  Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1508–12. Pubmed link
• 674  Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275–9. Pubmed link
• 675  Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: a double‐blind, randomized, placebo‐controlled trial. Arthritis Rheum 2008;59:1796–804. Cross Ref link Pubmed link
• 676  Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis 2012;15:62–8. Cross Ref link Pubmed link
• 677  Camara I, Sciascia S, Simoes J, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol 2014;32:41–7. Pubmed link
• 678  Griffiths B, Emery P, Ryan V, et al. The BILAG multi‐centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 2010;49:723–32. Cross Ref link Pubmed link
• 679  Cui TG, Hou FF, Ni ZH, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi‐center controlled clinical trial. Zhonghua Nei Ke Za Zhi 2005;44:672–6. Pubmed link
• 680  Wallace DJ. Plasmapheresis in lupus. Lupus 1993;2:141–3. Cross Ref link Pubmed link
• 681  Molina JF, McGrath H, Jr. Longterm ultraviolet‐A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 1997;24:1072–4. Pubmed link
• 682  Walton AJ, Snaith ML, Locniskar M, et al. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991;50:463–6. Cross Ref link Pubmed link
• 683  Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981;104:53–6. Cross Ref link Pubmed link
• 684  Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982;97:165–70. Cross Ref link Pubmed link
• 685  Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013;382(9894):809–18. Cross Ref link Pubmed link
• 686  Manzi S, Sanchez‐Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833–8. Cross Ref link Pubmed link